Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)

Assessment Status Assessment process complete
Drug Fluticasone furoate/ umeclidinium/ vilantero
Brand Trelegy™ Ellipta™
Indication For the maintenance treatment of adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.
Assessment Process
Rapid review commissioned 30/04/2018
Rapid review completed 18/06/2018
Rapid review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement; August 2018.